Siglec-9 Regulates an Effector Memory CD8 T-cell Subset That Congregates in the Melanoma Tumor Microenvironment.

Haas, Quentin; Frias Boligan, Kayluz; Jandus, Camilla; Schneider, Christoph; Simillion, Cedric; Stanczak, Michal A; Haubitz, Monika; Jafari, Morteza; Zippelius, Alfred; Baerlocher, Gabriela M.; Läubli, Heinz; Hunger, Robert E.; Romero, Pedro; Simon, Hans-Uwe; von Gunten, Stephan (2019). Siglec-9 Regulates an Effector Memory CD8 T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. Cancer immunology research, 7(5), pp. 707-718. American Association for Cancer Research 10.1158/2326-6066.CIR-18-0505

[img] Text
Simon_VonGunten_Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB)

Emerging evidence suggests an immunosuppressive role of altered tumor glycosylation due to downregulation of innate immune responses via immunoregulatory Siglecs. In contrast, human T cells, a major anticancer effector cell, only rarely express Siglecs. However, here, we report that the majority of intratumoral, but not peripheral blood, cytotoxic CD8 T cells expressed Siglec-9 in melanoma. We identified Siglec-9 CD8 T cells as a subset of effector memory cells with high functional capacity and signatures of clonal expansion. This cytotoxic T-cell subset was functionally inhibited in the presence of Siglec-9 ligands or by Siglec-9 engagement by specific antibodies. TCR signaling pathways and key effector functions (cytotoxicity, cytokine production) of CD8 T cells were suppressed by Siglec-9 engagement, which was associated with the phosphorylation of the inhibitory protein tyrosine phosphatase SHP-1, but not SHP-2. Expression of cognate Siglec-9 ligands was observed on the majority of tumor cells in primary and metastatic melanoma specimens. Targeting the tumor-restricted, glycosylation-dependent Siglec-9 axis may unleash this intratumoral T-cell subset, while confining T-cell activation to the tumor microenvironment.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

Graduate School:

Graduate School for Cellular and Biomedical Sciences (GCB)

UniBE Contributor:

Haas, Quentin, Frias Boligan, Kayluz, Jafari, Morteza, Baerlocher, Gabriela M., Hunger, Robert, Simon, Hans-Uwe, von Gunten, Stephan

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2326-6074

Publisher:

American Association for Cancer Research

Language:

English

Submitter:

Celine Joray

Date Deposited:

01 Jul 2019 14:56

Last Modified:

02 Mar 2023 23:32

Publisher DOI:

10.1158/2326-6066.CIR-18-0505

PubMed ID:

30988027

BORIS DOI:

10.7892/boris.130507

URI:

https://boris.unibe.ch/id/eprint/130507

Actions (login required)

Edit item Edit item
Provide Feedback